Luomo Siting (洛莫司汀)洛莫司汀
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 山东潍坊制药厂有限公司Chinese legal name: 山东潍坊制药厂有限公司
主要成分Active Ingredients
- 洛莫司汀Luomo Siting
药物知识说明
洛莫司汀是一种在国家药监局注册认定的药品。该药品含有洛莫司汀-26506b6b等成分。
该药品关联的活性成分包括：洛莫司汀Luomo Siting。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：山东潍坊制药厂有限公司Chinese legal name: 山东潍坊制药厂有限公司。
您可以探索含有相同成分的其他药品：洛莫司汀-26506b6b成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 洛莫司汀) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 洛莫司汀Luomo Siting.
Manufacturers recorded for this product: 山东潍坊制药厂有限公司Chinese legal name: 山东潍坊制药厂有限公司.
Explore other medicines containing the same ingredient: 洛莫司汀 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 洛莫司汀Recorded Chinese name: 洛莫司汀
- 规格Specification: ----
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 山东潍坊制药厂有限公司Chinese legal name: 山东潍坊制药厂有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H37020827
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H37020827
Manufacturer
Chinese legal name: 山东潍坊制药厂有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H37020827
生产企业
山东潍坊制药厂有限公司(国产)
适应症
1.本品脂溶性强，可通过血脑屏障，进入脑脊液，常用于脑部原发肿瘤(如成胶质细胞瘤)及继发性肿瘤。 2.治疗实体瘤，如联合用药治疗胃癌、直肠癌及支气管肺癌、恶性淋巴瘤等。
用法用量
口服，遵医嘱用。
不良反应
1.口服后6小时内可发生恶心、呕吐，可持续2～3天，预先用镇静药或甲氧氯普胺并空腹服药药可减轻。
2.少数患者发生胃肠道出血及肝功能损害。骨髓抑制，服药后3～5周可见血小板减少，白细胞降低可在服药后第1及第4周先后出现两次，第6～8周才恢复；但骨髓抑制有累计性。
3.偶见全身性皮疹，有致畸胎的可能，亦可能抑制睾丸或卵巢功能，引起闭经或精子缺乏。
禁忌
有肝功能损害、白细胞低于4×109/L、血小板低于80×109/L者禁用，合并感染时应先治疗感染。
注意事项
1.因可引起突变和畸变，孕妇及哺乳期妇女应禁用。
2.对诊断的干扰：本品可引起肝功能一时性异常。
3.下列情况慎用：骨髓抑制、感染、肾功能不全、经过放射治疗或抗癌药治疗的患者或有白细胞低下史者。
4.用药期间应注意随访检查血常规及血小板、血尿素氮、血尿酸、肌酐清除率、血胆红素、丙氨酸氨基转移酶等。
5.病人宜睡前与止吐药、安眠药共服，用药当天不能饮酒。
6.治疗前和治疗中应检查肺功能。
贮藏
遮光，密封保存。
规格
----
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.